Characterization of adverse reactions to four common targeted drugs for hepatocellular carcinoma in WHO-VigiAccess

Abstract Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality, with limited therapeutic options available for advanced stages of the disease. Treatment strategies for HCC are multimodal and largely depend on the disease stage, liver function, and individual patient...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Zeyu Wang, Jiyao Sheng, Xuewen Zhang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2025-05-01
Edice:	Scientific Reports
Témata:	Hepatocellular carcinoma Tyrosine kinase inhibitor VigiAccess Adverse drug reaction Adverse event
On-line přístup:	https://doi.org/10.1038/s41598-025-00004-7
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!